Lanreotide in the Treatment of Small Bowel Motility Disorders

Completed · Phase 2

Conditions studied: Gastrointestinal Motility Disorder, Intestinal Disease

In brief

This is a human research study looking at the effectiveness of Lanreotide (study medication) in treating small bowel motility disorders. It is similar to a natural hormone somatostatin that is produced in the body in the stomach, duodenum, pancreas and brain. Somatostatin is a growth hormone-inhibiting hormone. Lanreotide is a man made hormone and is a long acting medication that is given once a month. It is marketed with a trade name "Somatuline Depot". It is given deep subcutaneously (deep within the layers of the skin) in the superior external quadrant of the buttock. Injection site will be alternated on subsequent injections.

Key facts

Study ID

NCT03012594

Run by

Northwell Health

People needed

12

Starts

2017-05-11

Expected to finish

2019-03-11

Last updated by the study team

2021-01-15

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Consecutive patients with evidence of small bowel motility disorders, referred to (or) are patients of the Gastroenterology and Motility Center at Northwell Health System.
• Aged between 18 and 70 years.
• Subjects should be capable of understanding the study and be able to give informed consent.
• Patient having small bowel motility disorder as evidenced by delayed small bowel transit by wireless motility capsule (WMC) testing to > 6 hours.
• To participate in the study, patients will have to stop taking Octreotide (because it has the same mechanism of action as the study medication) if they are currently taking it; it should be stopped for at least 4 weeks before taking the first dose of this study medication.
• General Exclusion Criteria
• Age <18 or age >70
• Pregnancy as assessed by urine pregnancy test.
• Exclusion Criteria for performing wireless motility capsule testing
• History of gastric bezoar
• History of Disorders of swallowing
• Known or suspected small bowel diverticula, diverticulitis, strictures, fistulas, Crohn's disease, or any other relevant medical comorbidity (e.g. chronic alcohol abuse)
• Prior intestinal surgery, including Ileocecal(IC) valve resection or gastrointestinal surgeries that create a blind loop (e.g. Bilroth II or Roux-en-Y)
• History of Severe dysphagia to food or pills
• A participant who uses an implanted or portable electro-mechanical medical device such as a cardiac pacemaker or infusion pump
• Inability to be off intestinal transit altering medication for at least one week (e.g. opiates, laxatives, etc.)
• Any person unable or unwilling to undergo abdominal surgery.
• BMI > 40.
• Exclusion Criteria due to Lanreotide
• Current use or recent (within last 7 days) use of acid suppressive therapy, prokinetic agents, laxatives, and opiates, or other agents known to affect gastrointestinal motility.
• Disorders associated with presumed small intestinal motility disorders including: scleroderma, intestinal pseudo-obstruction, and autonomic visceral neuropathy (e.g. longstanding diabetes of more than 20 years and/or poorly controlled diabetes (glucose > 250, glycosylated hemoglobin (HbA1c) > 8.5%)
• Current use of cyclosporine (Gengraf, Neoral, or Sandimmune), a medicine called bromocriptine (Parlodel, Cycloset), or medicines that lower heart rate, such as beta blockers.
• Cardiac arrhythmia based on health history (palpitations, feeling a pause between heartbeats, lightheadedness, passing out, shortness of breath, or chest pain).
• Bradycardia and Tachycardia are monitored during every visit to the clinic, using pulse rate.
• ECG will be performed during screening visit and during 8th week of the study. The following are accessed with ECG.

Where it is running

• Long Island Jewish Medical Center — New Hyde Park, New York, United States
• Lenox Hill Hospital — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.